Clinical Trial Update: A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Ravagalimab (ABBV-323) for moderate to severe ulcerative colitis in patients who failed prior therapy; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Ravagalimab (ravagalimab)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis (UC) | Phase 2 | Status: COMPLETED | Results posted: 2023-03-15